Irinotecan for Advanced and Metastatic Breast Cancer

NCT03562390 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Irinotecan

Sponsor

Liaoning Cancer Hospital & Institute